GlassScriptPhysician profile
Denise Ricketts
NPI 1215163175
$10,843.27
in general payments reported to CMS, 2019-2025
51 companies · $1,707 in 2025
The $1,707 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $848 · 2020: $1,019 · 2021: $1,123 · 2022: $1,301 · 2023: $2,208 · 2024: $2,638 · 2025: $1,707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,378 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,378.13 |
| Education | $174.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,515.62 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $1,143.90 | 2019-2025 | |
| Lilly USA, LLC | $945.63 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $861.72 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $807.58 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $659.52 | 2021-2025 | |
| Amgen INC. | $597.76 | 2019-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $590.78 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $458.69 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $445.45 | 2019-2025 | |
| Abbott Laboratories | $414.26 | 2021-2025 | Freestyle Libre 3, Eterna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $213.64 | 2020-2023 | Xifaxan |
| Janssen Pharmaceuticals, INC | $182.07 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $167.75 | 2022-2024 | Ingrezza, Ongentys |
| Eisai INC. | $167.62 | 2020-2024 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denise Ricketts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.